Elite Pharmaceuticals Reports Q4 2026 Results: Full Earnings Call Transcript

Elite Pharmaceuticals (OTC: ELTP ) released fourth-quarter financial results and hosted an earnings call on Tuesday. Read the complete transcript below. This content is powered APIs. For comprehensive financial data and transcripts, visit The full earnings call is available at Summary Elite Pharmaceuticals Inc reported a substantial 77% increase in total revenues for fiscal year 2026, reaching $149 million, marking another year of record revenue growth.

Operating income rose by 151% to $49 million, attributed to a successful product line expansion and improved product mix yielding better margins. 7 million and a strengthening balance sheet, highlighted by a 163% increase in cash and a reduction in long-term debt by 20%. Elite Pharmaceuticals launched several new generic products over the past year, including methadone and filed for a generic coagulant, emphasizing their commitment to pipeline development and sustained growth.

Management highlighted the company's strong market position, successful internal product development strategy, and readiness for potential NASDAQ listing, underscoring a positive outlook for continued growth and investment attractiveness. Full Transcript OPERATOR Good morning, ladies and gentlemen, and welcome to the Elite Pharmaceuticals Year End of Fiscal Year 2026 conference call. At this time, all lines are placed on a listen-only mode.

Before management begins speaking, the conference has the following: Elite Pharmaceuticals Inc would like to remind listeners that remarks made during this call may contain forward-looking statements that involve risks and uncertainties that are subject to change at any time, including, but not limited to, statements about Elite's expectations regarding forward operating results. Forward-looking statements are made pursuant to the safe harbor provisions of the federal securities laws and represent management's current expectations. Actual results may differ materially.

Elite disclaims any obligation to update or revise its forward-looking statements except as required by law. com under the Investor Relations section. Elite encourages you to review these documents carefully. With that covered, it is now my pleasure to turn the floor over to your host, Mr.

Nasrat Hakim, President and Chief Executive Officer of Elite Pharmaceuticals. Sir, the floor is yours. Nasrat Hakim, President & CEO Thank you, Matthew. And good morning, ladies and gentlemen, and thank you for joining us today.

My name is Nasrat Hakim. I am Elite's Chairman and CEO. This is our earnings call. Our CFO, Carter Ward, will give us the financial update, after which I'll come back with a brief update and answer some of the questions you've submitted to Diane.

Mr. Ward, you have the floor. Carter Ward Thank you, Nasrat. And good morning, everybody.

Yesterday we filed our 10-K, which is our annual report for the fiscal year ended March 31, 2026. We're in a March fiscal year 10-K. com, under the Investor Relations section. Today, as usual, we're going to provide some context and some color to the financial statements and also answer the finance questions I received overnight and questions we got over the weekend even.

And as always, thank you so much for those questions. We really appreciate you taking the time to ask them. Let me start with the P&L first. Total revenues for the year were $149 million.

That's compared to $84 million for the March 2025 fiscal year last year. That is a $65 million increase, a 77% increase. Another year, another revenue record. So very impressive growth this year.

The Elite label. We're in our third year of the Elite label. The Elite label was launched in fiscal 2024. So 2026 is our third year, and let's look at how we've done since we've launched the Elite label.

In the first year, 2024, the revenues were $57 million, and that was a 66% increase over the year prior to launching. So we went from $57 million to the second year we were $84 million. That was last year. And this year, $149 million with a 77% increase.

Just to put some of this into perspective, we started this year from a baseline of record revenues. Last year was record revenues, and not only did we increase the actual dollars, but the percentage increase was also higher than it was last year. So that's pretty tough to do when the numbers get as big as they are now. When you're dealing in percentages, it's hard to increase the percentage.

So P&L is clear, solid, sustained growth strategy. How do we do it? It's typical generics. The strategy is straightforward.

Deliver quality product on time and as promised, to become the go-to supplier of choice in the market, which we are for our products, achieve a critical mass, which we've done, run efficiently, which we've always done, and most importantly, continue pipeline development. We need to develop, produce, develop new products, and launch new products. So further to this, the Elite label started three years ago with generic Adderall, Isradipine, Bendimetricine, a few other products.

And in the last two years, just to illustrate pipeline development, last two years, we've launched generic Vyvanse, generic Tylenol with codeine, generic Norco, generic Percocet, generic Otrexap, generic Revia. And we also brought in-house the old products, Naltrexone and Phentermine. We brought those back in-house, and now we're selling them exclusively on the Elite label. So it's clear that this is what explains what we reported on our financials this year, the 10-Ks, the 10-Qs.

And over the past few years,